Advertisement

Complications of Soft Tissue Bulking Agents Used in the Treatment of Urinary Leakage

  • Deborah J. LightnerEmail author
  • John J. Knoedler
Chapter
Part of the Current Clinical Urology book series (CCU)

Abstract

Why are bulking agents used for stress urinary incontinence? Mentally-based urinary incontinence occurring with increases in intra-abdominal pressure is the sign qua non of stress urinary incontinence and results from urethral failure to resist increases in intra-abdominal pressure. The proximate cause may be related to poor anatomic support of the urethra and bladder neck; this generally responds well to pelvic floor resuspension procedures of various types. Urethral failure, however, may be also intrinsic, meaning the urethral closure pressure is inefficient at resisting increases in intra-abdominal pressures; this is generally treated with sphincter augmentation procedures, which include periurethral bulking agents [1]. Of course, while there is considerable overlap between these two causes of stress urinary incontinence, treatment success with bulking agents used in the patient with predominantly poor anatomic support do not differ markedly from the treatment success in the patient with predominantly intrinsic sphincteric deficiency (ISD) [2, 3]. Conventionally, however, the use of bulking agents is more widely applied if the urinary loss related to poor urethral function without hypermobility.

Keywords

Urinary Incontinence Stress Urinary Incontinence Intrinsic Sphincteric Deficiency Urethral Closure Pressure Bulking Agent 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Klarskov N, Lose G. Urethral injection therapy: what is the mechanism of action? Neurourol Urodyn. 2008;27(8):789–92.PubMedCrossRefGoogle Scholar
  2. 2.
    Bent AE, Foote J, Siegel S, Faerber G, Chao R, Gormley EA. Collagen implant for treating stress urinary incontinence in women with urethral hypermobility. J Urol. 2001;166(4):1354–7.PubMedCrossRefGoogle Scholar
  3. 3.
    Zullo MA, Plotti F, Bellati F, Muzii L, Angioli R, Panici PB. Transurethral polydimethylsiloxane implantation: a valid option for the treatment of stress urinary incontinence due to intrinsic sphincter deficiency without urethral hypermobility. J Urol. 2005;173(3):898–902.PubMedCrossRefGoogle Scholar
  4. 4.
    Zullo MA, Ruggiero A, Montera R, et al. An ultra-miniinvasive treatment for stress urinary incontinence in complicated older patients. Maturitas. 2010;65(3): 292–5.PubMedCrossRefGoogle Scholar
  5. 5.
    Hamid R, Arya M, Khastgir J, Patel HRH, Shah PJR. The treatment of male stress urinary incontinence with polydimethylsiloxane in compliant bladders following spinal cord injury. Spinal Cord. 2003;41(5):286–9.PubMedCrossRefGoogle Scholar
  6. 6.
    Bennett JK, Green BG, Foote JE, Gray M. Collagen injections for intrinsic sphincter deficiency in the neuropathic urethra. Paraplegia. 1995;33(12):697–700.PubMedCrossRefGoogle Scholar
  7. 7.
    Wilson S, Quek ML, Ginsberg DA. Transurethral injection of bulking agents for stress urinary incontinence following orthotopic neobladder reconstruction in women. J Urol. 2004;172(1):244–6.PubMedCrossRefGoogle Scholar
  8. 8.
    Appell RA, Davila GW. Treatment options for patients with suboptimal response to surgery for stress urinary incontinence. Curr Med Res Opin. 2007;23(2):285–92.PubMedCrossRefGoogle Scholar
  9. 9.
    Plotti F, Zullo MA, Palaia I, Angioli R, Panici PB. Urinary incontinence after radical vulvectomy treated with macroplastique implantation. J Minim Invasive Gynecol. 2008;15(1):113–5.PubMedCrossRefGoogle Scholar
  10. 10.
    Comiter CV. Surgery insight: surgical management of postprostatectomy incontinence—the artificial urinary sphincter and male sling. Nat Clin Pract Urol. 2007;4(11):615–24.PubMedCrossRefGoogle Scholar
  11. 11.
    Brown JA, Elliott DS, Barrett DM. Postprostatectomy urinary incontinence: a comparison of the cost of conservative versus surgical management. Urology. 1998;51(5):715–20.PubMedCrossRefGoogle Scholar
  12. 12.
    Imamoglu MA, Tuygun C, Bakirtas H, Yigitbasi O, Kiper A. The comparison of artificial urinary sphincter implantation and endourethral macroplastique injection for the treatment of postprostatectomy incontinence. Eur Urol. 2005;47(2):209–13.PubMedCrossRefGoogle Scholar
  13. 13.
    Kylmala T, Tainio H, Raitanen M, Tammela TLJ. Treatment of postoperative male urinary incontinence using transurethral macroplastique injections. J Endourol. 2003;17(2):113–5.PubMedCrossRefGoogle Scholar
  14. 14.
    Westney OL, Bevan-Thomas R, Palmer JL, Cespedes RD, McGuire EJ. Transurethral collagen injections for male intrinsic sphincter deficiency: the University of Texas-Houston experience. J Urol. 2005;174(3):994–7.PubMedCrossRefGoogle Scholar
  15. 15.
    Roth CC, Donovan BO, Tonkin JB, Klein JC, Frimberger D, Kropp BP. Endoscopic injection of submucosal bulking agents for the management of incontinent catheterizable channels. J Pediatr Urol. 2009;5(4):265–8.PubMedCrossRefGoogle Scholar
  16. 16.
    Maeda Y, Laurberg S, Norton C. Perianal injectable bulking agents as treatment for faecal incontinence in adults. Cochrane Database Syst Rev. 2010(5): CD007959.Google Scholar
  17. 17.
    Ganz RA, Fallon E, Wittchow T, Klein D. A new injectable agent for the treatment of GERD: results of the Durasphere pilot trial. Gastrointest Endosc. 2009;69(2):318–23.PubMedCrossRefGoogle Scholar
  18. 18.
    Ghoniem G, Corcos J, Comiter C, Westney OL, Herschorn S. Durability of urethral bulking agent injection for female stress urinary incontinence: 2-year multicenter study results. J Urol. 2010;183(4):1444–9.PubMedCrossRefGoogle Scholar
  19. 19.
    Stenberg A, Larsson E, Lackgren G. Endoscopic treatment with dextranomer-hyaluronic acid for vesicoureteral reflux: histological findings. J Urol. 2003;169(3):1109–13.PubMedCrossRefGoogle Scholar
  20. 20.
    Radley SC, Chapple CR, Lee JA. Transurethral implantation of silicone polymer for stress incontinence: evaluation of a porcine model and mechanism of action in vivo. BJU Int. 2000;85(6):646–50.PubMedCrossRefGoogle Scholar
  21. 21.
    Dmochowski RR, Appell RA. Injectable agents in the treatment of stress urinary incontinence in women: where are we now? Urology. 2000;56(6 Suppl 1):32–40.PubMedCrossRefGoogle Scholar
  22. 22.
    Hurtado EA, McCrery RJ, Appell RA. Complications of ethylene vinyl alcohol copolymer as an intraurethral bulking agent in men with stress urinary incontinence. Urology. 2008;71(4):662–5.PubMedCrossRefGoogle Scholar
  23. 23.
    Haab F, Zimmern PE, Leach GE. Urinary stress incontinence due to intrinsic sphincteric deficiency: experience with fat and collagen periurethral injections [Erratum appears in J Urol. 1997;158(1):188]. J Urol. 1997;157(4):1283–6.PubMedCrossRefGoogle Scholar
  24. 24.
    Mitterberger M, Marksteiner R, Schwaiger W, et al. Can autologous myoblasts be used as a potential bulking agent? BJU Int. 2008;102(11):1731–6.PubMedCrossRefGoogle Scholar
  25. 25.
    Bent AE, Tutrone RT, McLennan MT, Lloyd LK, Kennelly MJ, Badlani G. Treatment of intrinsic sphincter deficiency using autologous ear chondrocytes as a bulking agent. Neurourol Urodyn. 2001;20(2):157–65.PubMedCrossRefGoogle Scholar
  26. 26.
    Lose G, Sorensen HC, Axelsen SM, Falconer C, Lobodasch K, Safwat T. An open multicenter study of polyacrylamide hydrogel (Bulkamid) for female stress and mixed urinary incontinence. Int Urogynecol J Pelvic Floor Dysfunct. 2010;21(12):1471–7.CrossRefGoogle Scholar
  27. 27.
    Aragona F, D’Urso L, Scremin E, Salmaso R, Glazel GP. Polytetrafluoroethylene giant granuloma and adenopathy: long-term complications following subureteral polytetrafluoroethylene injection for the treatment of vesicoureteral reflux in children. J Urol. 1997;158(4):1539–42.PubMedCrossRefGoogle Scholar
  28. 28.
    Malizia Jr AA, Reiman HM, Myers RP, et al. Migration and granulomatous reaction after periurethral injection of polytef (Teflon). JAMA. 1984;251(24):3277–81.PubMedCrossRefGoogle Scholar
  29. 29.
    Hubmer MG, Hoffmann C, Popper H, Scharnagl E. Expanded polytetrafluoroethylene threads for lip augmentation induce foreign body granulomatous reaction. Plast Reconstr Surg. 1999;103(4):1277–9.PubMedCrossRefGoogle Scholar
  30. 30.
    Toth G, Rubeiz H, Macdonald RL. Polytetrafluoroethylene-induced granuloma and brainstem cyst after microvascular decompression for trigeminal neuralgia: case report. Neurosurgery. 2007;61(4):E875–7; discussion E877.Google Scholar
  31. 31.
    Altomare DF, La Torre F, Rinaldi M, Binda GA, Pescatori M. Carbon-coated microbeads anal injection in outpatient treatment of minor fecal incontinence. Dis Colon Rectum. 2008;51(4):432–5.PubMedCrossRefGoogle Scholar
  32. 32.
    Tjandra JJ, Chan MKY, Yeh HCH. Injectable silicone biomaterial (PTQ) is more effective than carbon-coated beads (Durasphere) in treating passive faecal incontinence—a randomized trial. Colorectal Dis. 2009;11(4):382–9.PubMedCrossRefGoogle Scholar
  33. 33.
    Pannek J, Brands FH, Senge T. Particle migration after transurethral injection of carbon coated beads for stress urinary incontinence. J Urol. 2001;166(4):1350–3.PubMedCrossRefGoogle Scholar
  34. 34.
    Petrou SP, Pak RW, Lightner DJ. Simple aspiration technique to address voiding dysfunction associated with transurethral injection of dextranomer/hyaluronic acid copolymer. Urology. 2006;68(1):186–8.PubMedCrossRefGoogle Scholar
  35. 35.
    Hartanto VH, Lightner DJ, Nitti VW. Endoscopic evacuation of Durasphere. Urology. 2003;62(1): 135–7.PubMedCrossRefGoogle Scholar
  36. 36.
    Wainstein MA, Klutke CG. Periurethral pseudocyst following cystoscopic collagen injection. Urology. 1998;51(5):835–6.PubMedCrossRefGoogle Scholar
  37. 37.
    Sweat SD, Lightner DJ. Complications of sterile abscess formation and pulmonary embolism following periurethral bulking agents. J Urol. 1999;161(1): 93–6.PubMedCrossRefGoogle Scholar
  38. 38.
    Clemens JQ, Bushman W. Urethral diverticulum following transurethral collagen injection. J Urol. 2001;166(2):626.PubMedCrossRefGoogle Scholar
  39. 39.
    McLennan MT, Bent AE. Suburethral abscess: a complication of periurethral collagen injection therapy. Obstet Gynecol. 1998;92(4 Pt 2):650–2.PubMedCrossRefGoogle Scholar
  40. 40.
    Bridges MD, Petrou SP, Lightner DJ. Urethral bulking agents: imaging review. AJR Am J Roentgenol. 2005;185(1):257–64.PubMedGoogle Scholar
  41. 41.
    Leonard MP, Canning DA, Epstein JI, Gearhart JP, Jeffs RD. Local tissue reaction to the subureteral injection of glutaraldehyde cross-linked bovine collagen in humans. J Urol. 1990;143(6):1209–12.PubMedGoogle Scholar
  42. 42.
    Hanke CW, Higley HR, Jolivette DM, Swanson NA, Stegman SJ. Abscess formation and local necrosis after treatment with Zyderm or Zyplast collagen implant. J Am Acad Dermatol. 1991;25(2 Pt 1): 319–26.PubMedCrossRefGoogle Scholar
  43. 43.
    Bedir S, Kilciler M, Ozgok Y, Deveci G, Erduran D. Long-term complication due to dextranomer based implant: granuloma causing urinary obstruction. J Urol. 2004;172(1):247–8.PubMedCrossRefGoogle Scholar
  44. 44.
    Abdelwahab HA, Ghoniem GM. Obstructive suburethral mass after transurethral injection of dextranomer/hyaluronic acid copolymer. Int Urogynecol J Pelvic Floor Dysfunct. 2007;18(11):1379–80.PubMedCrossRefGoogle Scholar
  45. 45.
    Lightner DJ, Fox J, Klingele C. Cystoscopic injections of dextranomer hyaluronic acid into proximal urethra for urethral incompetence: efficacy and adverse outcomes. Urology. 2010;75(6):1310–4.PubMedCrossRefGoogle Scholar
  46. 46.
    Ko EY, Williams BF, Petrou SP. Bulking agent induced early urethral prolapse after distal urethrectomy. Int Urogynecol J Pelvic Floor Dysfunct. 2007;18(12):1511–3.PubMedCrossRefGoogle Scholar
  47. 47.
    Khalil A, Ghazeeri G, Chammas M, Usta I, Awwad J, Seoud M. Teflonoma presenting as a cystourethrocele. Clin Exp Obstet Gynecol. 2001;28(1):58–9.PubMedGoogle Scholar
  48. 48.
    Harris RL, Cundiff GW, Coates KW, Addison WA, Bump RC. Urethral prolapse after collagen injection. Am J Obstet Gynecol. 1998;178(3):614–5.PubMedCrossRefGoogle Scholar
  49. 49.
    Kulkarni S, Davies AJW, Treurnicht K, Dudderidge TJ, Al-Akraa M. Misplaced macroplastique injection presenting as a vaginal nodule and a bladder mass. Int J Clin Pract Suppl. 2005;147(Suppl):85–6.PubMedCrossRefGoogle Scholar
  50. 50.
    Hurtado E, McCrery R, Appell R. The safety and efficacy of ethylene vinyl alcohol copolymer as an intra-urethral bulking agent in women with intrinsic urethral deficiency. Int Urogynecol J Pelvic Floor Dysfunct. 2007;18(8):869–73.PubMedCrossRefGoogle Scholar
  51. 51.
    Carlin BI, Klutke CG. Development of urethrovaginal fistula following periurethral collagen injection. J Urol. 2000;164(1):124.PubMedCrossRefGoogle Scholar
  52. 52.
    Pruthi RS, Petrus CD, Bundrick Jr WS. New onset vesicovaginal fistula after transurethral collagen injection in women who underwent cystectomy and orthotopic neobladder creation: presentation and definitive treatment. J Urol. 2000;164(5):1638–9.PubMedCrossRefGoogle Scholar
  53. 53.
    Bernier PA, Zimmern PE, Saboorian MH, Chassagne S. Female outlet obstruction after repeated collagen injections. Urology. 1997;50(4):618–21.PubMedCrossRefGoogle Scholar
  54. 54.
    McKinney CD, Gaffey MJ, Gillenwater JY. Bladder outlet obstruction after multiple periurethral polytetrafluoroethylene injections. J Urol. 1995;153(1):149–51.PubMedCrossRefGoogle Scholar
  55. 55.
    Henly DR, Barrett DM, Weiland TL, O’Connor MK, Malizia AA, Wein AJ. Particulate silicone for use in periurethral injections: local tissue effects and search for migration. J Urol. 1995;153(6):2039–43.PubMedCrossRefGoogle Scholar
  56. 56.
    Solomon LZ, Birch BR, Cooper AJ, Davies CL, Holmes SA. Nonhomologous bioinjectable materials in urology: ‘size matters’? BJU Int. 2000;85(6):641–5.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Department of UrologyMayo ClinicRochesterUSA

Personalised recommendations